| December 26, 2011 | EISAI RESUBMITS AMPA RECEPTOR ANTAGONIST PERAMPANEL (E2007) NDA TO U.S. FDA |
| December 21, 2011 | EISAI SUBMITS APPLICATION FOR PARTIAL CHANGE TO LABEL OF
EGG WHITE LYSOZYME PREPARATION NEUZYM® |
| December 15, 2011 | EISAI ANNOUNCES CANADIAN APPROVAL OF ITS ANTICANCER AGENT HALAVEN™ |
| December 13, 2011 | EISAI SUBMITS APPLICATION IN JAPAN FOR NEW DRY SYRUP FORMULATION
OF ITS ALZHEIMER'S DISEASE TREATMENT ARICEPT® |
| December 2, 2011 | EISAI ANNOUNCES COMMENCEMENT OF OPERATIONS OF A NEW RESEARCH
FACILITY AT H3 BIOMEDICINE INC., A U.S. RESEARCH SUBSIDIARY TO FACILITATE
CUTTING-EDGE CANCER GENOMICS-DRIVEN DRUG DEVELOPMENT
-Aims to Provide Personalized Medicine by Integrating
Next-generation Synthetic Organic Chemistry with Patient-Based Cancer Genetics- |
| December 1, 2011 | EISAI'S CANADIAN SALES SUBSIDIARY CELEBRATES OFFICIAL
INTRODUCTION TO CANADA |
| November 30, 2011 | EISAI ANNOUNCES JAPAN LAUNCH OF
ORAL ANTICOAGULANT WARFARIN GRANULES 0.2% |
| November 18, 2011 | EISAI ENTERS INTO JAPAN CO-PROMOTION AGREEMENT WITH
NOVARTIS PHARMA FOR COPD THERAPIES |
| October 31, 2011 | EISAI SUPPORTS RELIEF EFFORTS FOR THAILAND FLOOD VICTIMS
-To Make US$100,000 Donation to Thailand Red Cross Society- |
| October 26, 2011 | EISAI JOINS WIPO SPONSORED GLOBAL CONSORTIUM
FOR NEGLECTED TROPICAL DISEASE RESEARCH AND DEVELOPMENT |
| October 17, 2011 | EISAI ENTERS INTO NEUROLOGICAL DRUG DISCOVERY RESEARCH
COLLABORATION WITH JOHNS HOPKINS UNIVERSITY |
| September 28, 2011 | Abbott Japan and Eisai Announce Launch of Humira® Prefilled Syringe 20mg/0.4mL,
a New Formulation for the Treatment of Juvenile Idiopathic Arthritis
in Patients with Low Body Weight |
| September 26, 2011 | Abbott Japan and Eisai Submit Application in Japan for Additional Indication of
Humira® (adalimumab), a Fully Human Anti-TNF-α Monoclonal Antibody,
for Inhibition of Structural Damage of Joints in Rheumatoid Arthritis |
| September 14, 2011 | SUPREME COURT OF JAPAN RULES TO EXTEND EISAI'S PATENT FOR
ARICEPT® IN RELATION TO SEVERE ALZHEIMER'S DISEASE |
| September 7, 2011 | EISAI TO ACCELERATE LATE-STAGE CLINICAL DEVELOPMENT OF
NEW DRUGS BY EFFECTIVELY LEVERAGING EXTERNAL RESOURCES
-Enters Collaborative Development Agreement with SFJ Pharmaceuticals for
Anticancer Agent E7080 (lenvatinib)- |
| September 6, 2011 | EISAI TO LAUNCH NEW SELBELLE® TABLETS AND
NEW SELBELLE® FINE GRANULES
New Medications to Alleviate Post Meal Stomach Heaviness |
| September 2, 2011 | EISAI DISCONTINUES DEVELOPMENT OF
PARIET®/ACIPHEX® EXTENDED-RELEASE CAPSULES, 50 MG |
| September 1, 2011 | EISAI PRESENTS NEW RESEARCH ON EPILEPSY PIPELINE,
PORTFOLIO AT THE 29TH INTERNATIONAL EPILEPSY CONGRESS
-Looks to Expand Global Epilepsy Product Portfolio- |
| August 31, 2011 | Toyama Chemical and Eisai Submit Marketing Authorization Application for
Anti-Rheumatic Agent T-614 |
| August 29, 2011 | Abbott Japan and Eisai Announce Launch of Pancreatic Digestive Enzyme Replacement Drug Lipacreon® (pancrelipase) |
| August 17, 2011 | EISAI ESTABLISHES SALES SUBSIDIARY IN MEXICO |
| August 10, 2011 | PROTOCO2L Carbon Dioxide Insufflation System for CT Colonography Receives Approval in Japan |
| August 2, 2011 | Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan) |
| July 29, 2011 | U.S. FDA PROVIDES RESPONSE TO PERAMPANEL NEW DRUG APPLICATION |
| July 28, 2011 | EMA ACCEPTS EISAI'S LICENSE EXTENSION APPLICATION FOR ANTIEPILEPTIC AGENT ZONEGRAN® AS A MONOTHERAPY |
| July 19, 2011 | EISAI ANNOUNCES JAPAN LAUNCH OF ANTICANCER AGENT HALAVEN® |
| July 14, 2011 | EISAI ANNOUNCES FDA ACCEPTANCE OF sNDA SUBMISSION FOR DACOGEN® IN ACUTE MYELOID LEUKEMIA |
| July 13, 2011 | EISAI ENTERS INTO COMPREHENSIVE CHINESE MARKETING AGREEMENT CONCERNING BREAST CANCER AND PARKINSON'S DISEASE TREATMENTS |
| July 7, 2011 | Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allotted |
| July 1, 2011 | Abbott Japan and Eisai Receive Approval in Japan for Additional Indication and New Formulation of Humira®, a Fully Human Anti-TNF-α Monoclonal Antibody, for the Treatment of Juvenile Idiopathic Arthritis |
| June 28, 2011 | EISAI'S ANTIEPILEPTIC AGENT BANZEL™ RECEIVES APPROVAL IN CANADA |
| June 24, 2011 | EUROPEAN MEDICINES AGENCY ACCEPTS FOR REVIEW EISAI'S MAA FOR AMPA RECEPTOR ANTAGONIST PERAMPANEL (E2007) |
| June 21, 2011 | Notice on Allocation of Stock Options (Stock Acquisition Rights) |
| June 10, 2011 | Information Regarding Voluntary Recall of Chocola® BB Sparkling (Vitamin Drink) Due to Mislabeling of Nutritional Information |
| June 7, 2011 | PHASE III STUDY OF DNA METHYLATION INHIBITOR DACOGEN® FOR INJECTION IN ACUTE MYELOID LEUKEMIA PRESENTED AT ASCO |
| June 2, 2011 | PHASE II STUDY RESULTS SHOWED EISAI'S LENVATINIB (E7080) DEMONSTRATED AN OBJECTIVE RESPONSE RATE OF 59% IN ADVANCED RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER |
| May 25, 2011 | EISAI-UNIVERSITY COLLEGE LONDON PARTNERSHIP ENTERS NEW PHASE |
| May 23, 2011 | EISAI TO DONATE $200,000 TO AMERICAN RED CROSS IN RESPONSE TO RECENT TORNADOES IN THE UNITED STATES |
| May 20, 2011 | EISAI RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF CALCIUM CHANNEL BLOCKING ANTI-ARRHYTHMIC AGENT VASOLAN® FOR PEDIATRIC PATEINTS IN JAPAN |
| May 20, 2011 | EISAI ONCOLOGY TO PRESENT NEW RESEARCH ON PRODUCT PORTFOLIO, PIPELINE AT ASCO ANNUAL MEETING |
| May 17, 2011 | CORRECTION TO CONSOLIDATED FINANCIAL REPORT FOR FISCAL 2010 |
| May 17, 2011 | EISAI'S HALAVEN® RECEIVES APPROVAL FROM SWISSMEDIC FOR USE IN LATE-STAGE METASTATIC BREAST CANCER |
| May 13, 2011 | Proposed Change of Representative Officers |
| May 13, 2011 | Issuance of Stock Acquisition Rights for the Purpose of Granting Stock Options to the Company's Employees |
| April 25, 2011 | FDA ISSUES COMPLETE RESPONSE LETTER FOR ARICEPT® PATCH (DONEPEZIL TRANSDERMAL SYSTEM) |
| April 22, 2011 | Abbott Japan and Eisai Receive Approval to Market the Pancreatic Digestive Enzyme Replacement Drug Lipacreon® (pancrelipase) in Japan |
| April 22, 2011 | HALAVEN® RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF INOPERABLE AND RECURRENT BREAST CANCER |
| April 8, 2011 | EISAI ESTABLISHES SALES SUBSIDIARY IN BRAZIL |
| April 5, 2011 | MORPHOTEK, INC. ACQUIRES TUMOR TARGETING ASSETS FROM TRANSMOLECULAR, INC.
Platform Technology Complements Morphotek's Antibody Targeting Technologies and Therapeutic Antibody Platform |
| April 4, 2011 | EISAI ENTERS INTO COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH PRISM BIOLAB CONCERNING CBP/β-CATENIN INHIBITING COMPOUNDS |
| March 31, 2011 | EISAI APPOINTS FIRST LOCALLY-HIRED PRESIDENT AT ITS CHINESE SUBSIDIARY EISAI CHINA INC.
-Aims to Make Further Contributions to Patients in China- |
| March 30, 2011 | Eisai and Minophagen Pharmaceutical Conclude Japan License Agreement for Cutaneous T-Cell Lymphoma Treatment Bexarotene |
| March 24, 2011 | LANDMARK RULING COMES INTO EFFECT: TREATMENT NOW AVAILABLE FOR PEOPLE IN ENGLAND AND WALES WITH MILD ALZHEIMER'S AT TIME OF DIAGNOSIS |
| March 23, 2011 | HALAVEN™ (ERIBULIN) RECEIVES EUROPEAN COMMISSION APPROVAL FOR ADVANCED BREAST CANCER |
| March 14, 2011 | EISAI TO OFFER DONATION TO TOHOKU PACIFIC EARTHQUAKE RELIEF FUND |
| March 11, 2011 | EISAI CONCLUDES WORLDWIDE STRATEGIC PARTNERSHIP WITH EPIZYME FOR CANCER THERAPEUTICS TARGETING EZH2 EPIGENETIC ENZYME |
| March 9, 2011 | Eisai and Sanko Junyaku to Launch Cobas h 232 Series, a Point-of-Care Testing System for Use in the Early Diagnosis of Cardiovascular Emergencies |
| March 4, 2011 | U.S. FDA APPROVES ANTI-EPILEPTIC AGENT BANZEL® (RUFINAMIDE) ORAL SUSPENSION, 40MG/ML
Indicated for Adjunctive Treatment of Seizures Associated With Lennox-Gastaut Syndrome in Children 4 Years and Older and Adults |
| March 3, 2011 | THE LANCET PUBLISHES RESULTS FROM PIVOTAL STUDY OF EISAI'S HALAVEN® IN PATIENTS WITH LATE-STAGE METASTATIC BREAST CANCER
Phase III Study Demonstrated that HALAVEN® Met its Primary Endpoint of Overall Survival |
| February 28, 2011 | EISAI TO DELAY NHI DRUG PRICE REGISTRATION AND LAUNCH OF NERBLOC®, A BOTULINUM TOXIN TYPE B NEUROMUSCULAR-BLOCKING AGENT |
| February 23, 2011 |
EISAI'S ORAL ANTICOAGULANT WARFARIN TABLETS APPROVED FOR PEDIATRIC USE IN JAPAN |
| February 23, 2011 |
INTELLECTUAL PROPERTY HIGH COURT OF JAPAN RULES TO MAINTAIN ARICEPT® PATENT TERM EXTENSION IN RELATION TO SEVERE ALZHEIMER'S DEMENTIA |
| February 22, 2011 |
Eisai, Sanko Junyaku Commence Co-promotion of DT-Navi, a New Touch-Screen System to Help Physicians with ADAS-Jcog. Testing and Assessment of Cognitive Function Change |
| February 21, 2011 |
EISAI TO EXPAND SALES OF CHOCOLA BB SERIES INTO ASIA -CHOCOLA BB® DRINK BIT SCHEDULED FOR LAUNCH IN HONG KONG- |
| February 14, 2011 |
EISAI CONCLUDES JAPAN LICENSE AGREEMENT FOR NEW ARICEPT® TRANSDERMAL FORMULATION |
| February 10, 2011 |
SINGAPORE HSA APPROVES EISAI’S HALAVEN® (ERIBULIN MESYLATE) INJECTION FOR TREATMENT OF METASTATIC BREAST CANCER |
| February 2, 2011 |
EISAI RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR INVESTIGATIONAL PROTON PUMP INHIBITOR ACIPHEX® EXTENDED-RELEASE CAPSULES, 50 MG |
| January 28, 2011 |
U.S. SUBSIDIARY H3 BIOMEDICINE INC. UNDERTAKES THE DEVELOPMENT OF NEXT-GENERATION CANCER DRUGS |
| January 25, 2011 |
EISAI TO SUBMIT MARKETING AUTHORIZATION APPLICATIONS IN THE U.S. AND EU FOR PERAMPANEL AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN PATIENTS WITH EPILEPSY |
| January 25, 2011 |
PHASE III STUDY FOR SEVERE SEPSIS TREATMENT ERITORAN (E5564) DOES NOT MEET PRIMARY ENDPOINT |
| January 25, 2011 |
NOTICE REGARDING CORPORATE NAME CHANGE OF SUBSIDIARY SANKO JUNYAKU CO., LTD. |
| January 24, 2011 |
HALAVEN™ RECEIVES CHMP POSITIVE OPINION FOR USE IN METASTATIC BREAST CANCER |
| January 21, 2011 |
EISAI RECEIVES APPROVAL TO MARKET BOTULINUM TOXIN TYPE B NEUROMUSCULAR-BLOCKING AGENT NERBLOC® INTRAMUSCULAR INJECTION 2500 UNITS IN JAPAN |
| January 18, 2011 |
FINAL NICE APPRAISAL RECOMMENDS IMPROVED ACCESS TO TREATMENT AND CARE OF PEOPLE WITH EARLY ALZHEIMER’S DISEASE |
| January 17, 2011 |
EISAI SIGNS PUBLIC-PRIVATE PARTNERSHIP AGREEMENT WITH APOLLO HOSPTIALS AND HELPAGE INDIA TO IMPROVE ACCESS TO MEDCINES IN INDIA |
| January 17, 2011 |
EISAI COMMENCES OPERATIONS AT NEW CHINESE PHARMACEUTICAL TRADING SUBSIDIARY |
| January 7, 2011 |
EISAI TO LAUNCH NEW ALLERGY MEDICATION SKAINAR® AL TABLETS |
